lenalidomide has been researched along with Exanthem in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 10 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagihara, M; Hanai, H; Inoue, M; Kubo, K; Kushi, R; Mita, M; Ohara, S; Sugi, T; Uchida, T; Yasu, T | 1 |
| Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Chapin, D; LaPlant, BR; Moustafa, MA; Parrondo, RD; Paulus, A; Roy, V; Sher, T | 1 |
| Buonomo, M; El Jurdi, N; Giubellino, A; Kabbur, G; Schultz, B | 1 |
| Gordon, A; Hassoun, H; Hollmann, TJ; Kuo, AM; Landau, HJ; Lesokhin, AM; Lezcano, C; Mailankody, S; Markova, A; Shah, U; Tan, CC | 1 |
| Jo, JC; Kim, HR; Kim, K; Kim, SH; Lee, JH; Lee, JJ; Lee, JY; Min, CK; Moon, JH; Shin, HJ | 1 |
| Aumann, S; Gatt, ME; Lebel, E; Parnasa, E; Ribak, Y; Rubin, L; Saban, R; Shamriz, O; Tal, Y; Talmon, A; Vainstein, V | 1 |
| Li, M; Wang, Q; Wang, X; Zeng, X | 1 |
| Eikenberg, JD; Grider, DJ; Patel, RT; Phillips, MA; Quan, EY | 1 |
| Beyaz, S; Buyukozturk, S; Colakoglu, B; Coskun, R; Demir, N; Demir, S; Gelincik, A; Kalayoglu-Besisik, S; Nalcacı, M; Ozkan, G; Paksoy, N | 1 |
| Hagihara, M; Hanai, H; Ide, S; Inoue, M; Mita, M; Nishigami, Y; Ohara, S; Saigo, H; Sugi, T; Takabatake, K; Uchida, T | 1 |
| Hagihara, M; Inoue, M; Mita, M; Ohara, S; Sugi, T; Uchida, T; Yasu, T | 1 |
| Betancourt Cuellar, SL; Cabanillas, ME; Falchook, GS; Fanale, MA; Fu, S; Glitza, IC; Hong, DS; Janku, F; Naing, A; Sakamuri, D; Subbiah, V; Tsimberidou, AM; Wheler, JJ | 1 |
| Almeida, A; Beach, CL; Castaneda, C; Fenaux, P; Garcia-Manero, G; Goldberg, SL; Gröpper, S; Jonasova, A; Santini, V; Vey, N; Zhong, J | 1 |
| Dote, S; Hira, D; Itakura, S; Ito, K; Kobayashi, Y; Noda, S; Terada, T; Yamada, S; Yasu, T | 1 |
| Baiocchi, OCCG; Batista, MD; Enokihara, MMSES; Gomes, EE; Sato-Sano, M; Teixeira, SP; Vargas, JC | 1 |
| Bahlis, NJ; Bailey, K; Duggan, P; Jimenez-Zepeda, VH; McCulloch, S; Neri, P; Tay, J; Yau, P | 1 |
| Garden, BC; Lacouture, ME; Nardone, B; Reich, LM; West, DP; Wu, S | 1 |
| Escudero-Vilaplana, V; Osorio Prendes, S; Sanjurjo Sáez, M | 1 |
| Cheah, CY; Fayad, LE; Fowler, NH; Hagemeister, FB; LeBlanc, D; Nastoupil, LJ; Neelapu, SS; Samaniego, F | 1 |
| Kurtin, SE; Ridgeway, JA; Tinsley, SM | 1 |
| Christos, P; Coleman, M; Furman, RR; Katz, O; Leonard, JP; Lewis, J; Martin, P; Rodriguez, A; Ruan, J; Schuster, SJ; Shah, B; Smith, SM; Svoboda, J | 1 |
| Agarwal, S; Barley, K; Chari, A; He, W; Jagannath, S | 1 |
| Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H | 1 |
| Alimena, G; Breccia, M; Cannella, L; Latagliata, R; Loglisci, G; Oliva, EN; Salaroli, A; Santopietro, M | 1 |
| Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R | 1 |
2 review(s) available for lenalidomide and Exanthem
| Article | Year |
|---|---|
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Topics: Angiogenesis Inhibitors; Exanthema; Humans; Incidence; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Practical Management of Lenalidomide-Related Rash.
Topics: Exanthema; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Thalidomide | 2015 |
6 trial(s) available for lenalidomide and Exanthem
| Article | Year |
|---|---|
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2022 |
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Ipilimumab; Lenalidomide; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Young Adult | 2018 |
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Diarrhea; Exanthema; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Spasm | 2018 |
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Prospective Studies; Rituximab; Thalidomide | 2015 |
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Quality of Life; Rituximab; Survival Analysis; Thalidomide | 2015 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Exanthema; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Quality of Life; Thalidomide; Thrombocytopenia | 2016 |
17 other study(ies) available for lenalidomide and Exanthem
| Article | Year |
|---|---|
Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2022 |
Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
Topics: Exanthema; Humans; Lenalidomide; Multiple Myeloma; Skin; Thalidomide | 2021 |
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Republic of Korea; Retrospective Studies | 2023 |
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Topics: Exanthema; Humans; Hypersensitivity, Delayed; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2023 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thalidomide | 2023 |
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema.
Topics: Drug Eruptions; Erythema; Exanthema; Humans; Lenalidomide; Skin | 2023 |
A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.
Topics: Adrenal Cortex Hormones; Adult; Aged; Desensitization, Immunologic; Drug Hypersensitivity; Eczema; Exanthema; Female; Humans; Lenalidomide; Male; Middle Aged; Parapsoriasis; Urticaria | 2019 |
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Risk Factors | 2021 |
Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Patient Acuity | 2021 |
Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Disease Susceptibility; Eosinophilia; Exanthema; Female; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Propensity Score | 2019 |
Lenalidomide in the management of eosinophilic dermatosis of hematological malignancy.
Topics: Eosinophilia; Exanthema; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pruritus; Skin; Treatment Outcome | 2019 |
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Topics: Aged; Aged, 80 and over; Cancer Care Facilities; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Outpatient Clinics, Hospital; Skin; Time Factors; Treatment Outcome | 2019 |
[Suspected itchy rash secondary to lenalidomide].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; Lenalidomide; Prednisone; Thalidomide | 2014 |
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Disease Management; Exanthema; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythroid Cells; Exanthema; Humans; Lenalidomide; Ribosomal Proteins; Thalidomide | 2011 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Depression; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prognosis; Recurrence; Risk Factors; Thalidomide; Treatment Outcome; Tremor | 2012 |